Savara (NASDAQ:SVRA) Stock Price Up 6.6% – Time to Buy?

Savara Inc. (NASDAQ:SVRA) rose 6.6% on Wednesday . The company traded as high as $5.26 and last traded at $5.2550. Approximately 278,516 shares changed hands during trading, a decline of 82% from the average daily volume of 1,514,531 shares. The stock had previously closed at $4.93.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SVRA. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright reaffirmed a “buy” rating on shares of Savara in a research report on Monday, March 16th. William Blair set a $10.00 target price on Savara in a report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. Finally, Oppenheimer assumed coverage on Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Savara currently has an average rating of “Moderate Buy” and a consensus price target of $10.14.

Savara Trading Up 3.1%

The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The business has a fifty day simple moving average of $5.30 and a 200 day simple moving average of $5.59. The company has a market cap of $1.04 billion, a P/E ratio of -9.08 and a beta of 0.26.

Savara (NASDAQ:SVRA) last released its earnings results on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Analysts anticipate that Savara Inc. will post -0.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Savara

A number of large investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP lifted its holdings in Savara by 371.1% in the first quarter. Seven Fleet Capital Management LP now owns 295,688 shares of the company’s stock worth $1,614,000 after acquiring an additional 232,926 shares during the last quarter. Avidity Partners Management LP bought a new position in Savara in the first quarter worth about $262,000. Glenmede Trust Co. NA bought a new position in Savara in the first quarter worth about $575,000. Bank of America Corp DE lifted its holdings in Savara by 38.9% in the first quarter. Bank of America Corp DE now owns 588,199 shares of the company’s stock worth $3,212,000 after acquiring an additional 164,603 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new position in Savara in the first quarter worth about $247,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.